Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1096622

USP

Carvedilol

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol, BM-14190

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C24H26N2O4
Numéro CAS:
72956-09-3
Poids moléculaire :
406.47
Numéro MDL:
MFCD00864692
Code UNSPSC :
41116107
ID de substance PubChem :
329749239
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

carvedilol

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC

InChI

1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3

Clé InChI

OGHNVEJMJSYVRP-UHFFFAOYSA-N

Informations sur le gène

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146) , ADRB1(153) , ADRB2(154) , ADRB3(155)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carvedilol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Carvedilol Tablets

Actions biochimiques/physiologiques

Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000103

Carvedilol impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001427

Carvedilol, European Pharmacopoeia (EP) Reference Standard

Y0001426

Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard

1096644

Carvedilol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1096677

Carvedilol Related Compound E, United States Pharmacopeia (USP) Reference Standard

1096633

Carvedilol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1096666

Carvedilol Related Compound D, United States Pharmacopeia (USP) Reference Standard

1096655

Carvedilol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1096688

Carvedilol System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

PHR2434

Carvedilol Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2435

Carvedilol Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2952

Carvedilol Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2953

Carvedilol Related Compound C, pharmaceutical secondary standard, certified reference material

Pictogrammes

Health hazardEnvironment
GHS08,GHS09

Mention d'avertissement

Warning

Mentions de danger

H373,H411

Classification des risques

Aquatic Chronic 2 - STOT RE 2

Organes cibles

Liver,spleen,Uterus (including cervix),Adrenal gland

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Gonçalo C Pereira et al.
Current pharmaceutical design, 17(20), 2113-2129 (2011-07-02)
Mitochondria have long been involved in several cellular processes beyond its role in energy production. The importance of this organelle for cardiac tissue homeostasis has been greatly investigated and its impairment can lead to cell death and consequent organ failure.
James J DiNicolantonio et al.
The American journal of cardiology, 113(3), 565-569 (2013-12-18)
A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials. Ovid MEDLINE, PubMed, CENTRAL, and Excepta Medica
Carol Chen-Scarabelli et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions, 12(6), 391-401 (2012-10-16)
β-Adrenergic receptor antagonists (β-blockers) have been recognized for their cardioprotective properties, prompting use of these pharmacologic agents to become more mainstream in acute myocardial infarction (AMI) and congestive heart failure (CHF). Despite their popularity as a class, the ability to
Adrian J Stanley et al.
Journal of hepatology, 61(5), 1014-1019 (2014-06-24)
Rebleeding after an initial oesophageal variceal haemorrhage remains a significant problem despite therapy with band ligation, non-selective β-blockers or a combination of these. Carvedilol is a vasodilating non-selective β-blocker with alpha-1 receptor and calcium channel antagonism. A recent study has
Subhashis Chakraborty et al.
Expert opinion on drug metabolism & toxicology, 6(2), 237-250 (2010-01-16)
Carvedilol, a non-selective beta-blocker, has recently drawn attention because of its therapeutic benefits over other prescribed analogues for the treatment of cardiovascular diseases (CVDs). The present review attempts to present the clinical efficacy of carvedilol in comparison to other available
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique